Research Article
Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases
Table 1
Baseline characteristics.
| | Baseline characteristics | Total DKA | EuDKA | hDKA |
| | Number of cases, N (%) | 29 (100%) | 14 (48.2%) | 15 (51.8%) | | Gender, N (%) | | | | | Male | 10 (40%) | 7 (50%) | 4 (30.8%) | | Female | 15 (60%) | 7 (50%) | 9 (69.2%) | | SGLT2i agent, N (%) | | | | | Canagliflozin | 10 (34.4%) | 3 (21.4%) | 7 (46.6%) | | Empagliflozin | 12 (41.3%) | 7 (50%) | 5 (33.3%) | | Dapagliflozin | 7 (24.1%) | 4 (28.6%) | 3 (20.1%) | | Duration of diabetes, mean + SD, years | 8.76 ± 5.73 | 9.08 ± 6.4 | 8.46 ± 5.28 | | Prior DKA, N (%) | | | | | Yes | 2 (8%) | 2 (14.2%) | 2 (15.4%) | | No | 23 (92%) | 12 (85.8%) | 11 (84.6%) | | Age, mean ± SD, years | 54.24 ± 12.41 | 55.64 ± 11.65 | 52.93 ± 13.3 | | Average BMI, mean ± SD, kg/m2 | 30.64 ± 6.29 | 29.86 ± 5.46 | 31.37 ± 7.09 | | A1c, mean ± SD, % | 9.71 ± 3.05 | 9.16 ± 3.1 | 10.19 ± 3.03 |
|
|
One male patient had one episode of euDKA and one episode of hDKA, and one female patient had one episode of euDKA and three episodes of hDKA.
|
